FY2025 · ended Dec 31, 2025 · Revenue $4.41M, +8.8% YoY · Filed Mar 4, 2026
Ocugen, Inc. (OCGN) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $4.4 million and a net loss of $67.8 million. Free cash flow was -$57.1 million. As of Sep 30, 2026 it held $84.3 million in cash and investments and $5.4 million in total debt.
Revenue (TTM)
$4.78M
-11.0% vs year-ago TTM
Net income (TTM)
$-65.36M
-2.1% vs year-ago TTM
Operating cash flow (TTM)
$-63.69M
-19.3% vs year-ago TTM
Free cash flow (TTM)
$-63.90M
-19.4% vs year-ago TTM
EPS
$-0.26
+35.0% vs prior year
Dividend per share
None
Shares outstanding
327.90M
+12.3% vs prior year
Net cash
$78.81M
as of Sep 30, 2026
Operating margin
-1444.1%
FY 2026
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- OCGN (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Malvern, PA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1372299
- Former names
- HISTOGENICS CORP (until Sep 26, 2019)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $4.4M | $4.1M | $6.0M | — | $0 |
| Operating income | -$62.9M | -$54.8M | -$65.5M | -$89.1M | -$58.0M |
| Net income | -$67.8M | -$54.1M | -$63.1M | -$86.8M | -$58.4M |
| Diluted EPS | — | — | -$0.26 | -$0.40 | -$0.30 |
| Operating cash flow | -$57.0M | -$42.1M | -$62.1M | -$60.1M | -$47.9M |
| Free cash flow | -$57.1M | -$45.5M | -$72.5M | -$64.5M | -$48.9M |
| Total assets | $43.5M | $82.4M | $64.5M | $108.6M | $105.8M |
| Total liabilities | $55.7M | $52.8M | $24.0M | $34.7M | $9.9M |
| Stockholders' equity | -$12.2M | $29.6M | $40.6M | $74.0M | $91.2M |
| Cash and investments | $18.6M | $58.5M | $39.5M | $90.9M | $95.0M |
| Total debt | $33.1M | $32.5M | $6.9M | $6.4M | $3.3M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 4, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 4, 2026 | Nov 4, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Oct 15, 2026 | Oct 15, 2026 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure, Other events
|
Oct 15, 2026 | Oct 13, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Oct 6, 2026 | Oct 5, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Sep 23, 2026 | Sep 21, 2026 |
All 892 Ocugen, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.